Evolent Health, Inc. (NYSE:EVH) Given Consensus Rating of "Buy" by Brokerages

Evolent Health, Inc. (NYSE:EVH - Get Free Report) has received a consensus recommendation of "Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $17.92.

Several research firms have commented on EVH. BTIG Research dropped their target price on Evolent Health from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Tuesday, December 3rd. Stephens decreased their price target on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a research note on Tuesday, January 21st. Barclays decreased their price target on Evolent Health from $39.00 to $19.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. Canaccord Genuity Group decreased their price target on Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Finally, UBS Group decreased their target price on Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, January 16th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Evolent Health by 12.8% in the third quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company's stock valued at $356,200,000 after purchasing an additional 1,426,747 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Evolent Health by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 11,171,199 shares of the technology company's stock valued at $125,676,000 after purchasing an additional 259,781 shares in the last quarter. Engaged Capital LLC lifted its holdings in shares of Evolent Health by 35.5% in the fourth quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company's stock valued at $60,804,000 after purchasing an additional 1,415,300 shares in the last quarter. Cadian Capital Management LP bought a new position in shares of Evolent Health in the fourth quarter valued at approximately $58,781,000. Finally, Eventide Asset Management LLC lifted its holdings in shares of Evolent Health by 1.7% in the third quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company's stock valued at $107,580,000 after purchasing an additional 64,985 shares in the last quarter.

Evolent Health Trading Up 1.0 %

Evolent Health stock traded up $0.10 during trading hours on Friday, hitting $10.07. The stock had a trading volume of 1,745,560 shares, compared to its average volume of 2,244,315. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -11.06 and a beta of 1.45. Evolent Health has a one year low of $9.45 and a one year high of $35.00. The business's 50 day simple moving average is $10.84 and its 200-day simple moving average is $19.13.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.